

Francesca Spada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8924644/publications.pdf>

Version: 2024-02-01

49
papers

843
citations

567281

15
h-index

501196

28
g-index

49
all docs

49
docs citations

49
times ranked

1361
citing authors

#	ARTICLE	IF	CITATIONS
1	A Multinational Pilot Study on Patients'™ Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires. <i>Journal of Clinical Medicine</i> , 2022, 11, 1271.	2.4	1
2	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. <i>JAMA Network Open</i> , 2022, 5, e220290.	5.9	21
3	Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors. <i>Updates in Surgery</i> , 2022, 74, 1697-1704.	2.0	4
4	Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside. <i>Current Oncology Reports</i> , 2022, 24, 715-722.	4.0	2
5	Multidisciplinary team approach for Merkel cell carcinoma: the European Institute of Oncology experience with focus on radiotherapy. <i>Tumori</i> , 2021, 107, 145-149.	1.1	5
6	Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. <i>Endocrine</i> , 2021, 72, 268-278.	2.3	10
7	Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3 rd -line treatment. <i>World Journal of Gastroenterology</i> , 2021, 27, 976-989.	3.3	3
8	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 94, 102168.	7.7	6
9	A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy. <i>Diagnostics</i> , 2021, 11, 804.	2.6	5
10	INTENSIVE: InterNaTional rEgistry oN Sars-cov-2 posltiVe nEuroendocrine neoplasm patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16205-e16205.	1.6	0
11	Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. <i>Pharmaceuticals</i> , 2021, 14, 539.	3.8	7
12	Looking for the right TNM staging system for pancreatic neuroendocrine tumors. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 382-384.	1.5	2
13	Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. <i>Current Treatment Options in Oncology</i> , 2021, 22, 73.	3.0	6
14	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021, 39, 2304-2312.	1.6	49
15	Reply to comments on "COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a worldwide survey (The INTENSIVE study)"™. <i>European Journal of Cancer</i> , 2021, 157, 531-532.	2.8	0
16	Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. <i>European Journal of Cancer</i> , 2021, 154, 246-252.	2.8	4
17	A Retrospective Analysis of the Correlation between Functional Imaging and Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3). <i>Diagnostics</i> , 2021, 11, 2401.	2.6	1
18	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. <i>Annals of Surgery</i> , 2020, 271, 527-533.	4.2	44

#	ARTICLE	IF	CITATIONS
19	The rare entity of bilateral and unilateral neuroendocrine metastases to the breast: a case series and literature review. <i>Ecancermedicalsecience</i> , 2020, 14, 1123.	1.1	6
20	Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas. <i>Neuroendocrinology</i> , 2019, 109, 100-112.	2.5	27
21	Should platinum-based chemotherapy be preferred for germline BRCA1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2019, 80, 101895.	7.7	32
22	Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 993-1004.	3.3	15
23	A retrospective series of centralized reviewed GEP MANECs receiving a first-line adenocarcinoma-oriented chemotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, e15695-e15695.	1.6	1
24	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , 2018, 18, 198-203.	1.1	18
25	Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2018, 3, e000389.	4.5	4
26	A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. <i>Journal of Thoracic Disease</i> , 2018, 10, 3928-3939.	1.4	15
27	Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 71, 39-46.	7.7	14
28	The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. <i>Neuroendocrinology</i> , 2017, 104, 85-93.	2.5	185
29	Metronomic and metronomic-like therapies in neuroendocrine tumors – Rationale and clinical perspectives. <i>Cancer Treatment Reviews</i> , 2017, 55, 46-56.	7.7	7
30	When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1487-1488.	1.6	3
31	Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. <i>Targeted Oncology</i> , 2017, 12, 611-622.	3.6	20
32	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017, 6, 1493-1499.	2.8	11
33	Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2017, 18, 419-449.	1.2	4
34	The role of multimodal treatment in patients with advanced lung neuroendocrine tumors. <i>Journal of Thoracic Disease</i> , 2017, 9, S1501-S1510.	1.4	18
35	Successful palliative approach with high-intensity focused ultrasound in a patient with metastatic anaplastic pancreatic carcinoma: a case report. <i>Ecancermedicalsecience</i> , 2016, 10, 635.	1.1	8
36	Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 981-989.	1.5	58

#	ARTICLE	IF	CITATIONS
37	Histologically-Proven Efficacy of Bland Embolization in a Patient with Net Liver Metastasis. CardioVascular and Interventional Radiology, 2016, 39, 948-952.	2.0	0
38	Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. Neuroendocrinology, 2016, 103, 806-814.	2.5	61
39	A single-Institution retrospective analysis of metastatic bronchial carcinoids with a focus on recurrence pattern.. Journal of Clinical Oncology, 2016, 34, e20586-e20586.	1.6	0
40	Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside. Cancer Treatment Reviews, 2015, 41, 754-760.	7.7	19
41	Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making. International Journal of Surgery, 2015, 20, 58-64.	2.7	20
42	Chemotherapy with capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NENs): an Italian multicenter retrospective analysis.. Journal of Clinical Oncology, 2015, 33, e15174-e15174.	1.6	9
43	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. Oncologist, 2014, 19, 966-974.	3.7	84
44	RAF signaling in neuroendocrine neoplasms: From bench to bedside. Cancer Treatment Reviews, 2014, 40, 974-979.	7.7	21
45	Capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NEN): An Italian multicenter retrospective analysis.. Journal of Clinical Oncology, 2014, 32, 281-281.	1.6	10
46	Updated overall survival and time to progression results in NETs treated with everolimus combination with octreotide LAR as first-line treatment.. Journal of Clinical Oncology, 2014, 32, e15160-e15160.	1.6	1
47	Long-term survival after multidisciplinary treatment of small-bowel neuroendocrine tumors with synchronous liver metastases. AA single-institute experience.. Journal of Clinical Oncology, 2013, 31, 299-299.	1.6	0
48	Long-term survival after multidisciplinary treatment of small-bowel neuroendocrine tumors with synchronous liver metastases: A single-institute experience.. Journal of Clinical Oncology, 2013, 31, e15147-e15147.	1.6	0
49	Clinical Response after Sorafenib for Hepatocellular Carcinoma in Elderly Patients: A Report of Two Cases. Tumori, 2012, 98, e53-e56.	1.1	2